SCHEMBL18182103

SCHEMBL18182103

CN1CCC(Nc2ccc(Br)cc2N)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
AAK1 Q2M2I8 4/20 0.41
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 1/20 0.39
KAT2B Q92831 2/20 0.39
ALOX15 P16050 2/20 0.39
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HDAC1 Q13547 1/20 0.37
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
EHMT2 Q96KQ7 1/20 0.36
KMT2A Q03164 1/20 0.35
HRH4 Q9H3N8 2/20 0.35
FPR2 P25090 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980977 1.00 POLB (0.43) POLBAAK1CYP3A4CYP2D6KAT2B
SCHEMBL29791970 0.91 AAK1 (0.42) POLBAAK1CYP3A4CYP2D6KAT2B
SCHEMBL28536643 0.91 AAK1 (0.42) POLBAAK1CYP3A4CYP2D6KAT2B
SCHEMBL23177340 0.91 AAK1 (0.42) POLBAAK1CYP3A4CYP2D6KAT2B
SCHEMBL30980984 0.91 AAK1 (0.42) POLBAAK1CYP3A4CYP2D6KAT2B
SCHEMBL23177128 0.91 AAK1 (0.42) POLBAAK1CYP3A4CYP2D6KAT2B
SCHEMBL1519578 0.88 POLB (0.43) POLBCYP3A4CYP2D6KAT2BKDM4E
SCHEMBL29502212 0.85 AAK1 (0.48) AAK1ALOX15KDM4EGAAMAPT
SCHEMBL459719 0.85 AAK1 (0.48) AAK1ALOX15KDM4EGAAMAPT
SCHEMBL2946261 0.82 MAPT (0.56) AAK1ALOX15KDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497392-B2 EP300/CBP inhibitor HINOVA PHARMACEUTICALS INC. (CN) 2025-12-16 US disclosed
US-20230027088-A1 EP300/CBP INHIBITOR HINOVA PHARMACEUTICALS INC. (CN) 2023-01-26 US disclosed
EP-4043458-A1 EP300/CBP INHIBITOR Hinova Pharmaceuticals Inc. (CN) 2022-08-17 EP disclosed
CN-113166139-A Pyrrolo [2,3-b ] pyridines as HPK1 inhibitors and uses thereof 百济神州有限公司 2021-07-23 CN disclosed
WO-2021057915-A1 EP300/CBP INHIBITOR 成都海创药业有限公司 2021-04-01 WO disclosed
US-10118920-B2 Isoxazolyl substituted benzimidazoles CELLCENTRIC LTD (GB) 2018-11-06 US disclosed
US-20180127402-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES CELLCENTRIC LTD (GB) 2018-05-10 US disclosed
US-20180127402-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES CELLCENTRIC LTD (GB) 2018-05-10 US disclosed
US-20180127402-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES CELLCENTRIC LTD (GB) 2018-05-10 US disclosed
WO-2016170324-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES CELLCENTRIC LTD (GB) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497392-B2 EP300/CBP inhibitor EP300, MLLT1, CREBBP POLB 4012/4885AAK1 861/4885CYP3A4 3971/4885
US-20180127402-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES EP300, HDAC3, HDAC1 POLB 2057/4885AAK1 3594/4885CYP3A4 1300/4885
US-20230027088-A1 EP300/CBP INHIBITOR EP300, MLLT1, CREBBP POLB 4012/4885AAK1 861/4885CYP3A4 3971/4885
US-10118920-B2 Isoxazolyl substituted benzimidazoles EP300, HDAC3, HDAC1 POLB 2057/4885AAK1 3594/4885CYP3A4 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.